Advertisement
Digestive and Liver Disease
Advanced searchSave search
Meta-Analysis|Articles in Press

Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis

Published:September 01, 2022DOI:https://doi.org/10.1016/j.dld.2022.08.017
Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis
Previous ArticleEfficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma
Next ArticleImpact of surgical resection for gastrointestinal stromal tumor (GIST) patients with initially diagnosed synchronous hepatic metastases on long-term survival outcomes

      Abstract

      Background

      Diabetes Mellitus (DM) may occur in IBD and influence the disease progression.

      Aim

      To compare disease course and treatment outcomes in IBD patients with and without DM.

      Methods

      This is a systematic review with meta-analysis comparing patients with IBD plus DM with patients with IBD only. Primary endpoints: need for surgery, IBD-related complications, hospitalizations, sepsis, mortality. Quality of life and costs were assessed.

      Results

      Five studies with 71,216 patients (49.1% with DM) were included. Risk for IBD-related complications (OR=1.12, I2 98% p = 0.77), mortality (OR=1.52, I2 98% p = 0.37) and IBD-related surgery (OR=1.20, I2 81% p = 0.26) did not differ. Risk of IBD-related hospitalizations (OR=2.52, I2 0% p < 0.00001) and sepsis (OR=1.56, I2 88% p = 0.0003) was higher in the IBD+DM group. Risk of pneumonia and urinary tract infections was higher in the IBD+DM group (OR=1.72 and OR=1.93), while risk of C. Difficile infection did not differ (OR=1.22 I2 88% p = 0.37). Mean Short Inflammatory Bowel Disease Questionnaire score was lower in the IBD+DM group (38.9 vs. 47, p = 0.03). Mean health care costs per year were $10,598.2 vs $3747.3 (p < 0.001).

      Conclusion

      DM might negatively affect the course of IBD by increasing the risk of hospitalization and infections, but not IBD-related complications and mortality.

      Keywords

      Abbreviations:

      IBD (Inflammatory Bowel Disease), DM (Diabetes Mellitus), SIBDQ (Short Inflammatory Bowel Disease Questionnaire), CD (Crohn's Disease), UC (Ulcerative Colitis), QoL (Quality of Life), OR (Odds Ratio), HR (Hazard Ratio), UTI (Urinary tract infection)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Flynn S.
        • Eisenstein S.
        Inflammatory bowel disease presentation and diagnosis.
        Surg Clin North Am. 2019; 99: 1051-1062
        View in Article
        • Fu Y.
        • Lee C.H.
        • Chi C.C.
        Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis.
        JAMA Dermatol. 2018; 154: 1417-1423
        View in Article
        • Kuenzig M.E.
        • Bishay K.
        • Leigh R.
        • Kaplan G.G.
        • Benchimol E.I.
        Crowdscreen SR review team. co-occurrence of asthma and the inflammatory bowel diseases: a systematic review and meta-analysis.
        Clin Transl Gastroenterol. 2018; 9: 188
        View in Article
        • Maahs D.M.
        • West N.A.
        • Lawrence J.M.
        • EJ Mayer-Davis
        Epidemiology of type 1 diabetes.
        Endocrinol Metab Clin North Am. 2010; 39: 481-497
        View in Article
        • Shaw J.E.
        • Sicree R.A.
        • Zimmet P.Z.
        Global estimates of the prevalence of diabetes for 2010 and 2030.
        Diabetes Res Clin Pract. 2010; 87: 4-14
        View in Article
        • Zheng P.
        • Li Z.
        • Zhou Z.
        Gut microbiome in type 1 diabetes: a comprehensive review.
        Diabetes Metab Res Rev. 2018; 34: e3043
        View in Article
        • Redondo M.J.
        • Steck A.K.
        • Pugliese A.
        Genetics of type 1 diabetes.
        Pediatr Diabetes. 2018; 19: 346-353
        View in Article
        • Gjymishka A.
        • Coman R.M.
        • Brusko T.M.
        • Glover S.C.
        Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.
        Immunotherapy. 2013; 5: 1357-1366
        View in Article
        • Wang K.
        • Baldassano R.
        • Zhang H.
        • et al.
        Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects.
        Hum Mol Genet. 2010; 19: 2059-2067
        View in Article
        • Lu S.
        • Gong J.
        • Tan Y.
        • Liu D.
        Epidemiologic association between inflammatory bowel diseases and Type 1 diabetes mellitus: a meta-analysis.
        J Gastrointestin Liver Dis. 2020; 29: 407-413
        View in Article
        • Wilson J.C.
        • Furlano R.I.
        • Jick S.S.
        • Meier C.R.
        Inflammatory bowel disease and the risk of autoimmune diseases.
        J Crohns Colitis. 2016; 10: 186-193
        View in Article
        • Din H.
        • Anderson A.J.
        • Ramos Rivers C.
        • Proksell S.
        • Koutroumpakis F.
        • Salim T.
        • Babichenko D.
        • Tang G.
        • Koutroubakis I.E.
        • Schwartz M.
        • Johnston E.
        • Barrie A.
        • Harrison J.
        • Hashash J.
        • Dunn M.A.
        • Hartman D.J.
        • Binion D.G
        Disease characteristics and severity in patients with inflammatory bowel disease with coexistent diabetes mellitus.
        Inflamm Bowel Dis. 2020; 26: 1436-1442
        View in Article
        • Kumar A.
        • Teslova T.
        • Taub E.
        • Miller J.D.
        • Lukin D.J.
        Comorbid diabetes in inflammatory bowel disease predicts adverse disease-related outcomes and infectious complications.
        Dig Dis Sci. 2021; 66: 2005-2013
        View in Article
        • Page M.J.
        • McKenzie J.E.
        • Bossuyt P.M.
        • Boutron I.
        • Hoffmann T.C.
        • Mulrow C.D.
        • Shamseer L.
        • Tetzlaff J.M.
        • Akl E.A.
        • Brennan S.E.
        • Chou R.
        • Glanville J.
        • Grimshaw J.M.
        • Hróbjartsson A.
        • Lalu M.M.
        • Li T.
        • Loder E.W.
        • Mayo-Wilson E.
        • McDonald S.
        • McGuinness L.A.
        • Stewart L.A.
        • Thomas J.
        • Tricco A.C.
        • Welch V.A.
        • Whiting P.
        • Moher D.
        The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
        J Clin Epidemiol. 2021; 134: 178-189
        View in Article
        • Stroup D.F.
        • Berlin J.A.
        • Morton S.C.
        • et al.
        Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
        JAMA. 2000; 283: 2008-2012
        View in Article
        • Mantel N.
        • Haenszel W.
        Statistical aspects of the analysis of data from retrospective studies of disease.
        J Natl Cancer Inst. 1959; 22: 719-748
        View in Article
        • Higgins J.P.
        • Thompson S.G.
        • Deeks J.J.
        • et al.
        Measuring inconsistency in metaanalyses.
        BMJ. 2003; 327: 557-560
        View in Article
        • Guyatt G.H.
        • Oxman A.D.
        • Vist G.E.
        • Kunz R.
        • Falck-Ytter Y.
        • Alonso-Coello P.
        • Schünemann H.J.
        • Working Group G.R.A.D.E.
        GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
        BMJ. 2008; 336: 924-926
        View in Article

      19. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013.

        View in Article
        • Sterne J.A.C.
        • Hernán M.A.
        • Reeves B.C.
        • Savović J.
        • Berkman N.D.
        • Viswanathan M.
        • Henry D.
        • Altman D.G.
        • Ansari M.T.
        • Boutron I.
        • Carpenter J.R.
        • Chan A.W.
        • Churchill R.
        • Deeks J.J.
        • Hróbjartsson A.
        • Kirkham J.
        • Jüni P.
        • Loke Y.K.
        • Pigott T.D.
        • Ramsay C.R.
        • Regidor D.
        • Rothstein H.R.
        • Sandhu L.
        • Santaguida P.L.
        • Schünemann H.J.
        • Shea B.
        • Shrier I.
        • Tugwell P.
        • Turner L.
        • Valentine J.C.
        • Waddington H.
        • Waters E.
        • Wells G.A.
        • Whiting P.F.
        • Higgins J.P.T.
        ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions.
        BMJ. 2016; 355: i4919https://doi.org/10.1136/bmj.i4919
        View in Article
        • Uwagbale E.
        • Adeniran O.G.
        • Adeniran O.A.
        • Onukogu I.
        • Agbroko S.
        • Sonpal N.
        In-hospital outcomes of inflammatory bowel diseases in patients with diabetes mellitus: a propensity score matching analysis.
        Cureus. 2021; 13: e16566
        View in Article
        • Harper J.W.
        • Welch M.P.
        • Sinanan M.N.
        • Wahbeh G.T.
        • Lee S.D.
        Co-morbid diabetes in patients with Crohn's disease predicts a greater need for surgical intervention.
        Aliment Pharmacol Ther. 2012; 35: 126-132
        View in Article
        • Ananthakrishnan A.N.
        • Cagan A.
        • Cai T.
        • Gainer V.S.
        • Shaw S.Y.
        • Churchill S.
        • Karlson E.W.
        • Murphy S.N.
        • Kohane I.
        • Liao K.P.
        Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
        Aliment Pharmacol Ther. 2015; 41: 1141-1148
        View in Article
        • Irvine E.J.
        • Zhou Q.
        • Thompson A.K.
        The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators Canadian Crohn's Relapse Prevention Trial.
        Am J Gastroenterol. 1996; 91: 1571-1578
        View in Article
        • Burisch J.
        • Munkholm P.
        The epidemiology of inflammatory bowel disease.
        Scand J Gastroenterol. 2015; 50: 942-951
        View in Article
        • Vignali A.
        • Fazio V.W.
        • Lavery I.C.
        • Milsom J.W.
        • Church J.M.
        • Hull T.L.
        • Strong S.A.
        • Oakley J.R.
        Factors associated with the occurrence of leaks in stapled rectal anastomoses: a review of 1,014 patients.
        J Am Coll Surg. 1997; 185: 105-113
        View in Article
        • Choi J.K.
        • Kim D.W.
        • Shin S.Y.
        • Park E.C.
        • Kang J.G.
        Effect of ulcerative colitis on incidence of colorectal cancer: results from the nationwide population-based cohort study (2003–2013).
        J Cancer. 2016; 7: 681-686
        View in Article
        • Villumsen M.
        • Schelde A.B.
        • Jimenez-Solem E.
        • Jess T.
        • Allin K.H
        GLP-1 based therapies and disease course of inflammatory bowel disease.
        EClinicalMedicine. 2021; 37100979
        View in Article
        • Wheat C.L.
        • Ko C.W.
        • Clark-Snustad K.
        • Grembowski D.
        • Thornton T.A.
        • Devine B.
        Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis.
        BMC Gastroenterol. 2017; 17 (PMID: 28407755; PMCID: PMC5391579): 52https://doi.org/10.1186/s12876-017-0602-0
        View in Article
        • Munkholm P.
        • Langholz E.
        • Davidsen M.
        • Binder V.
        Frequency of glucocorticoid resistance and dependency in Crohn's disease.
        Gut. 1994; 35: 360-362
        View in Article
        • Li Z.
        • Qiao L.
        • Yun X.
        • Du F.
        • Xing S.
        • Yang M.
        Increased risk of ischemic heart disease and diabetes in inflammatory bowel disease.
        Z Gastroenterol. 2021; 59: 117-124
        View in Article

      Article info

      Publication history

      Published online: September 01, 2022
      Accepted: August 4, 2022
      Received: May 20, 2022

      Publication stage

      In Press Corrected Proof

      Identification

      DOI: https://doi.org/10.1016/j.dld.2022.08.017

      Copyright

      © 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX